Browse the evidence

SIRT1 activation via calorie restriction or resveratrol promotes mitochondrial biogenesis through PGC-1α deacetylation, which may reduce reactive oxygen species (ROS) production and mitigate aging.

Calorie restriction and potentially resveratrol may improve health by activating SIRT1, which boosts mitochondrial biogenesis via PGC-1α. This process might reduce oxidative stress by making mitochondria more efficient, though this specific benefit is not yet proven in humans. Focus on metabolic health rather than fearing oxidative stress from increased metabolism.

Resveratrol, a SIRT1 activator, counteracts adverse consequences of a high-calorie diet in mice, including extending lifespan and improving metabolic health, by promoting mitochondrial biogenesis.

Resveratrol has shown benefits in mice on high-calorie diets by activating SIRT1 and improving mitochondrial function. However, human evidence is limited to short-term metabolic improvements, and the mechanism of action is debated. It is not a substitute for a healthy diet and lifestyle.

Curcumin administration significantly reduces blood glucose levels and improves insulin sensitivity in rodent models of diabetes (STZ-induced, alloxan-induced, and high-fat diet-induced).

In animal studies, curcumin consistently lowered blood sugar and improved insulin sensitivity across various diabetes models. While human data is limited, the mechanism suggests potential benefit for glycemic control, particularly when using formulations designed to improve absorption.

Curcumin ameliorates diabetes-associated complications including neuropathy, nephropathy, and vascular dysfunction through anti-inflammatory and antioxidant mechanisms.

Curcumin shows promise in reducing the risk of diabetes complications like nerve and kidney damage in animal studies by lowering inflammation and oxidative stress. Human application requires more robust clinical trials.

Gut microbiota composition influences obesity risk through the production of short-chain fatty acids (SCFAs), where butyrate and propionate act as anti-obesogenic agents by improving insulin sensitivity and regulating appetite, while acetate acts as an obesogenic substrate for lipogenesis.

Your gut bacteria produce chemicals that directly affect your weight. Some byproducts (butyrate, propionate) help control hunger and fat storage, while others (acetate) can fuel fat creation. To support the beneficial byproducts, prioritize fiber-rich foods that feed the specific bacteria that produce them, rather than just focusing on calorie counting.

High-fat diets increase the absorption of lipopolysaccharides (LPS) from Gram-negative bacteria, leading to metabolic endotoxemia, chronic inflammation, and increased adiposity.

High-fat diets can damage your gut barrier, allowing bacterial toxins (LPS) into your bloodstream. This triggers inflammation that promotes fat storage and insulin resistance. Reducing excessive fat intake and supporting gut barrier integrity may help mitigate this inflammatory response.

Inhibition of miR-103 and miR-107 using the GalNAc-conjugated antagomiR RG-125 (AZD4076) improves hepatic insulin sensitivity and reduces liver triglyceride content in patients with type 2 diabetes or pre-diabetes.

This research highlights a specific pharmaceutical approach (RG-125) targeting liver fat and insulin resistance in diabetic patients. As of the paper's writing, this was in early clinical trials. For now, managing hepatic insulin resistance relies on standard lifestyle interventions (caloric deficit, exercise) and existing medications, keeping an eye on emerging therapies that target specific molecular pathways like miR-103/107.

Interrupting sedentary behavior does not significantly improve lipidemia (blood fats) in adults.

Breaking up sitting time will not lower your cholesterol or triglycerides. Focus on other strategies for lipid management.

Chronic treatment with the beta-3 adrenergic receptor agonist mirabegron increases brown adipose tissue (BAT) metabolic activity and volume in healthy women without altering body weight.

This study suggests that the bladder medication Mirabegron, when taken chronically at a dose higher than standard (100mg vs 50mg), can activate brown fat and increase its volume in healthy women without causing weight gain. However, because the study was small, open-label, and lacked a placebo, these results should be viewed as preliminary evidence that beta-3 stimulation is a viable pathway for metabolic health, pending larger controlled trials.

Chronic mirabegron treatment improves insulin sensitivity, glucose effectiveness, and pancreatic beta-cell function in healthy women.

Mirabegron, taken at 100mg daily for 4 weeks, significantly improved insulin sensitivity and glucose handling in healthy women. This suggests beta-3 stimulation is a potent lever for metabolic health, though the high dose used here caused mild cardiovascular side effects, suggesting future drugs need better selectivity.

Chronic mirabegron treatment increases plasma levels of HDL cholesterol, ApoA1, and bile acids, independent of weight loss.

Mirabegron treatment improved favorable lipid markers (HDL, ApoA1) and bile acids. This may be a downstream effect of increased brown fat activity consuming lipoproteins. This benefit occurred without weight loss.

Gut microbiota dysbiosis in women with Polycystic Ovary Syndrome (PCOS) is significantly associated with clinical phenotypes, including elevated testosterone, increased waist circumference, and altered brain-gut peptides (serotonin, ghrelin, PYY).

This research suggests that the gut health of women with PCOS differs from controls, specifically showing lower levels of beneficial bacteria (like Akkermansia) and higher levels of potentially inflammatory bacteria (like Escherichia/Shigella). These microbial differences are linked to higher testosterone and waist circumference. While this study does not prescribe a specific diet, it supports the investigation of dietary interventions aimed at improving gut microbiota diversity as a potential strategy to manage PCOS symptoms.

High-fructose diets promote visceral adipose tissue accumulation and insulin resistance, which indirectly drives intrahepatic lipid accumulation by increasing the flux of free fatty acids from adipose tissue to the liver.

Fructose may contribute to belly fat (visceral adiposity) more than glucose in some studies. This belly fat releases fatty acids into the liver, worsening fatty liver. This is an indirect effect. Managing overall weight and insulin sensitivity is key to reducing this flux.

Alpha-hydroxybutyrate (a-HB) inhibits glucose-induced insulin release, while linoleoyl-glycerophosphocholine (L-GPC) stimulates it, providing a physiological mechanism for their predictive value regarding beta-cell dysfunction.

This paper explains why these markers matter: a-HB directly suppresses insulin secretion, while L-GPC enhances it. This suggests that high a-HB and low L-GPC are not just passive signs of disease but actively contribute to beta-cell failure. However, this was shown in rat cells, so human application is theoretical.

Gamma-linolenic acid (GLA) improves the efficacy and reduces the side effects of tamoxifen in breast cancer patients, including improving transcutaneous absorption.

If you are taking tamoxifen for breast cancer, ask your oncologist about adding GLA. Research suggests it may help the drug work better, reduce side effects, and potentially speed up how quickly you respond to therapy. It may also help deliver the drug more effectively through the skin if using topical forms.

Gamma-linolenic acid (GLA) exhibits tumoricidal activity against various cancers (breast, pancreas, colon, brain) and inhibits metastasis by downregulating osteonectin and stimulating metastasis suppressor genes.

GLA shows promise in laboratory and some clinical settings for fighting cancer cells and preventing spread, particularly when combined with standard treatments. It may help reduce side effects of chemotherapy and improve drug efficacy. Consult your oncologist before use.

Dietary nitrate may reduce arterial stiffness and intimal hyperplasia, and protect against ischaemia-reperfusion injury, primarily through nitric oxide generation and inhibition of oxidative stress.

While most evidence for reduced arterial stiffness and protection against tissue damage is from animal studies, the mechanism suggests that a diet rich in nitrate-containing vegetables may support vascular health and reduce aging-related arterial stiffening.

Physical activity reduces colon cancer risk through multiple biological mechanisms including reduced insulin levels, faster gut transit time, and altered prostaglandin levels.

Exercise helps prevent colon cancer by lowering insulin levels, speeding up digestion, and changing hormone levels in the gut. These biological changes create an environment less favorable for cancer development.

Soy Protein Isolate (SPI) and purified soy isoflavones (genistein, daidzein) exhibit weak estrogenic activity that may pose risks for reproductive health, early development, and estrogen-sensitive cancers, despite conflicting evidence from some human studies.

If you are taking soy protein isolate or purified soy isoflavone supplements (not just eating tofu/edamame), be aware they have weak estrogenic effects. Women with a history of endometriosis or estrogen-sensitive cancers should consult a doctor before using these supplements, as they may increase risk. Infants should generally be fed cow milk formula unless soy is medically indicated.

ATF3 acts as a master regulator of metabolic homeostasis and oncogenesis, functioning as a context-dependent hub that can either suppress or promote disease states depending on tissue type and cellular stress.

This paper identifies ATF3 as a critical biological switch in metabolism and cancer. While not a direct intervention for humans yet, it suggests that therapies targeting ATF3 induction (like ST32da) or inhibition could treat metabolic disorders and cancers. Current research focuses on how stress signals trigger ATF3 to regulate glucose and fat storage.

ATF3 plays a dual role in prostate cancer, acting as a tumor suppressor by inhibiting androgen signaling and AKT, but also as an oncogene by promoting cell proliferation and metastasis via SUMOylation.

ATF3's role in prostate cancer is complex. It can suppress tumors by blocking androgen signals but can also promote cancer if modified by SUMOylation. This complexity makes it a challenging but potentially valuable target for therapy.

Rapamycin inhibits the Stat3 pathway, which may explain its ability to suppress SASP independently of Nrf2.

Rapamycin may reduce inflammation in aging cells by turning off the Stat3 signal, even if the cell's main antioxidant system (Nrf2) is broken.

Type 2 diabetes is associated with an increased risk of specific cancers, including endometrial, colorectal, breast, pancreatic, liver, and kidney cancers, while being associated with a decreased risk of prostate cancer.

If you have Type 2 diabetes, be aware that your risk for certain cancers (like breast, colorectal, and pancreatic) is higher, while your risk for prostate cancer may be lower. Regular screening appropriate for your age and gender is crucial.

Metformin use in patients with diabetes is associated with a reduced risk of cancer and cancer-specific mortality, although methodological biases in early studies may have inflated these estimates.

If you take Metformin for diabetes, you may benefit from a potential reduction in cancer risk, although this is not yet definitively proven. Continue taking it as prescribed for your diabetes management.